Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. by nantkweststg | Feb 12, 2021
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. by nantkweststg | Feb 12, 2021
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies by nantkweststg | Jan 28, 2021
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations by nantkweststg | Jan 28, 2021
Recent Comments